These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 1306076)

  • 1. Plasma t-PA and PAl-1 antigen concentrations in non-insulin dependent diabetic patients: effects of treatment modality on fibrinolysis.
    Cho YW; Yang DH; Oh DY; Baick SH; Kim SK; Kim SJ; Hong SY
    Korean J Intern Med; 1992 Jul; 7(2):81-6. PubMed ID: 1306076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma t-PA and PAI-1 antigen concentrations in non-insulin dependent diabetic patients: implication for diabetic retinopathy.
    Cho YW; Yang DH; Oh DY; Baick SH; Kim SK; Kim SJ; Hong SY
    Diabetes Res Clin Pract; 1994 Jan; 22(2-3):123-8. PubMed ID: 8200293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased fibrinolytic potential induced by gliclazide in types I and II diabetic patients.
    Gram J; Jespersen J
    Am J Med; 1991 Jun; 90(6A):62S-66S. PubMed ID: 1908183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrinolysis and diabetic retinopathy in NIDDM.
    Mansfield MW; Grant PJ
    Diabetes Care; 1995 Dec; 18(12):1577-81. PubMed ID: 8722054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Tissue-type plasminogen activator and its inhibitor (PAI-1) in plasma in cases of non-insulin-dependent diabetes mellitus (NIDDM)].
    Jokaji H; Asakura H; Saito M; Uotani C; Kumabashiri I; Morishita E; Yamazaki M; Matsuda T
    Nihon Ronen Igakkai Zasshi; 1990 Nov; 27(6):699-705. PubMed ID: 2127812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
    Kruszynska YT; Yu JG; Olefsky JM; Sobel BE
    Diabetes; 2000 Apr; 49(4):633-9. PubMed ID: 10871202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No influence of proinsulin and insulin on plasma levels of plasminogen activator inhibitor type 1 and tissue plasminogen activator in young women before and during intake of contraceptive steroids.
    Petersen KR; Kjems LL; Skouby SO; Andersen LF; Jespersen J
    Metabolism; 1996 Jul; 45(7):833-7. PubMed ID: 8692017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrinolytic measurements in type 2 diabetic patients with acute cerebral infarction.
    Mansfield MW; Catto AJ; Carter AM; Grant PJ
    Diabet Med; 1998 Nov; 15(11):953-7. PubMed ID: 9827850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of obesity on fibrinolytic activity and plasma lipoprotein (a) levels in patients with type 2 diabetes mellitus in Korea.
    Park YS; Park S; Park KS; Kim SY; Lee HK; Koh CS; Min HK; Kim JQ
    Diabetes Res Clin Pract; 1994 May; 24(1):25-31. PubMed ID: 7924883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between plasminogen activator inhibitor-1 and insulin resistance in newly diagnosed type 2 diabetes mellitus.
    Gough SC; Rice PJ; McCormack L; Chapman C; Grant PJ
    Diabet Med; 1993; 10(7):638-42. PubMed ID: 8403825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of strict metabolic control by insulin infusion on fibrinolytic profile during an acute coronary event in diabetic patients.
    Melidonis A; Stefanidis A; Tournis S; Manoussakis S; Handanis S; Zairis M; Dadiotis L; Foussas S
    Clin Cardiol; 2000 Mar; 23(3):160-4. PubMed ID: 10761802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Plasminogen activators (t-PA and u-PA) and other fibrinolysis parameters in patients with atherosclerosis obliterans and diabetic macroangiopathy].
    Zalewska-Rydzkowska D; Rość D; Ponikowska I; Michalski A; Graczykowska-Koczorowska A; Rydzkowski M
    Pol Merkur Lekarski; 2001 Nov; 11(65):414-7. PubMed ID: 11852811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rise of plasma t-PA fibrinolytic activity in a group of maturity onset diabetic patients shifted from a first generation (tolbutamide) to a second generation sulphonylurea (gliclazide).
    Gram J; Kold A; Jespersen J
    J Intern Med; 1989 Apr; 225(4):241-7. PubMed ID: 2498455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of gliclazide on platelet aggregation and the plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus.
    Konya H; Hasegawa Y; Hamaguchi T; Satani K; Umehara A; Katsuno T; Ishikawa T; Miuchi M; Kohri K; Suehiro A; Kakishita E; Miyagawa J; Namba M
    Metabolism; 2010 Sep; 59(9):1294-9. PubMed ID: 20070990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus.
    Auwerx J; Bouillon R; Collen D; Geboers J
    Arteriosclerosis; 1988; 8(1):68-72. PubMed ID: 2449156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of tissue-type plasminogen activator-mediated fibrinolysis by plasminogen activator inhibitor type-1 in patients with ischaemic heart disease: possible unfavourable effect of diuretics.
    Pedersen OD; Gram J; Bagger H; Keller N; Jespersen J
    Coron Artery Dis; 1994 Jul; 5(7):617-23. PubMed ID: 7952424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction.
    Wright RA; Flapan AD; Alberti KG; Ludlam CA; Fox KA
    J Am Coll Cardiol; 1994 Jul; 24(1):67-73. PubMed ID: 8006284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects.
    Al-Hamodi Z; Ismail IS; Saif-Ali R; Ahmed KA; Muniandy S
    Cardiovasc Diabetol; 2011 Mar; 10():23. PubMed ID: 21414238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of rosiglitazone treatment on the fibrinolytic system in patients with type 2 diabetes mellitus.
    Guldiken S; Turgut B; Demir M; Arikan E; Kara M; Vural O; Tugrul A; Fareed J
    Clin Appl Thromb Hemost; 2006 Jan; 12(1):55-60. PubMed ID: 16444435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of fibrinolysis in poorly controlled, hospitalized type 2 diabetic patients by short-term metabolic control: association with a decrease in plasminogen activator inhibitor 1.
    Aso Y; Okumura KI; Yoshida N; Tayama K; Takemura Y; Inukai T
    Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):175-80. PubMed ID: 15127320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.